Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

Inclusion Criteria: Only subjects who meet all of the following criteria will be eligible to participate in this study: * Male patients * Age ≥ 45 years * Suspected presence of prostate inflammatory foci, defined according to the following criteria: * PSA ≥ 2.6 ng/mL and age ≥ 50 and \< 60 years (or ≥ 45 years if the patient has known family predisposition to carcinoma of the prostate) or, * PSA ≥ 4.1 ng/mL and age ≥ 60 and \< 75 years, and * normal digito-rectal examination (DRE) (see section 5.2), and normal urine test with dipstick and/or microscopy carried out within 5 days of the baseline visit * Patients willing and able to provide their written informed consent and to comply with study procedures. * Patients with LUTS/BPH on watchful waiting or already under treatment with alpha-blockers or 5-ARI (5-alpha reductase inhibitors) for at least 6 months will also be considered eligible to participate in the study. Exclusion Criteria: Patients who meet any of the following criteria will not be eligible to participate in this study: * Diagnosis of NIH class I-III prostatitis or clinical evidence of active acute urinary infection and/or known or suspected active bacterial infection at other sites; * Diagnosis of prostate carcinoma (or PIN or ASAPS) or prior radical prostatectomy or radiotherapy or other treatments for prostate cancer; * PSA \> 20 ng/mL; * PSA values (including high values) stable over time; * Start of a pharmacological therapy with 5-ARI in subjects with LUTS/BPH; * Permanent catheter; * Prior treatment (within 4 weeks) with levofloxacin for genital-urinary infections; * Known or suspected allergy to levofloxacin, including the excipients contained in the pharmacological preparation and/or confirmed tendency to photosensitivity reactions after fluoroquinolone therapy; * Concomitant treatment with drugs not allowed in the study * Reluctance to undergo prostate biopsy and/or risk of non-compliance; * History or current evidence of alcohol or drug abuse in the last 12 months; * History of any conditions that, in the opinion of the investigator, may confound the study results or create additional risks for the patient. * Participation in any study of investigational or marketed drugs within 30 days before the baseline visit or during the study.